BioSpace News Archive

A new Lupus Foundation of America study on hydroxychloroquine (HCQ) treatment and adherence confirms the gravity of experiential factors, such as medication impression and patient-reported symptom improvement, in HCQ treatment adherence.

Watercrest Senior Living Group proudly announces that Hollie Kemp, Watercrest’s Chief Experience Officer, has been selected as a 2019 Argentum Senior Living Leader under 40.

Less than three months into his first term, State Senator Kevin Thomas has co-sponsored three bills that take away fundamental medical, religious and parental rights that New Yorkers have always had.

National Seating & Mobility (NSM), the leading provider of complex rehabilitation, mobility and accessibility solutions in the U.S., is broadening the company’s presence in British Columbia, Canada with the acquisition of Advanced Mobility Products in Vancouver

Prime Healthcare hospitals have been named among the nation’s “100 Top Hospitals” by IBM Watson Health™ in an annual study identifying top-performing hospitals in the United States.

Hospice Savannah will be recognized by Mutual of America for its We the Living program during a special hometown luncheon and award presentation at the Perry Lane Ballroom in Savannah today at 12:00 p.m.

A global data analytics and advisory firm, Quantzig, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of their latest healthcare analytics engagement for a leading player in the specialty drugs market.

Emergency visits climbed to a record high of 145.6 million patients in 2016, the most recent year available, according to new data from the Centers for Disease Control and Prevention (CDC).

WaveForm Technologies Inc. a wholly owned subsidiary of AgaMatrix Holdings LLC and developer of novel products for continuous glucose monitoring, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the WaveForm Technologies Continuous Glucose Monitor (CGM).

Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion.